Study: Autistic Children May Need Fewer Hours of Treatment Than Previously Thought
21 nov. 2023 13h41 HE
|
Catalight
Walnut Creek, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Each year, tens of thousands of parents and caregivers of children with autism spectrum disorder (ASD) face vital decisions: What kind of...
Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder
20 nov. 2023 08h05 HE
|
Yamo Pharmaceuticals
Yamo Pharmaceuticals LLC has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents with autism spectrum disorder (ASD).
Catalight Honored as a Healthy People 2030 Champion from Department of Health and Human Services
15 nov. 2023 13h40 HE
|
Catalight
Walnut Creek, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Citing the company’s bold vision for the future, Catalight was recently named a Healthy People 2030 Champion by the Office of Disease...
Neurological Biomarkers Research Report 2023: A Global $18.75 Billion Market by 2030 with Pipeline Analysis of Alzheimer's, Parkinson's, Multiple Sclerosis, & Autism Spectrum Disorder
14 nov. 2023 05h28 HE
|
Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type,...
Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
06 nov. 2023 12h00 HE
|
NeuroQure
IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum...
Hopebridge Launches Standardized Circle Time Curriculum in Autism Therapy Centers Across the Country
30 oct. 2023 08h00 HE
|
Hopebridge
Indianapolis, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Children with autism spectrum disorder (ASD) will now have even more support in their transition to school due to an innovative Circle Time Curriculum...
Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism
26 sept. 2023 08h00 HE
|
Axial Therapeutics
– Topline clinical data anticipated in 1Q 2024 – – First-in-class small molecule therapeutic targets the microbiome gut-brain axis and its role in autism, offering a potential alternative to...
Baylor Genetics Announces Neurodevelopmental Disorders Test Panel to Help Healthcare Providers Diagnose Patients with Intellectual Disabilities or Developmental Delays
12 sept. 2023 08h00 HE
|
Baylor Genetics
HOUSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, today announced the availability of a new Neurodevelopmental...
Celebrate a New Sesame Street Friend with My Friend Julia: A Sesame Street® Book about Autism by Jennifer Cook
07 sept. 2023 12h08 HE
|
Lerner Publishing Group
Minneapolis, Minnesota, Sept. 07, 2023 (GLOBE NEWSWIRE) -- This September, Lerner Publications™, an imprint of Lerner Publishing Group™, presents My Friend Julia: A Sesame Street® Book about Autism...
Hopebridge Autism Therapy Centers celebrates school-readiness graduations for children across the country
28 août 2023 09h00 HE
|
Hopebridge
Indianapolis, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hundreds of children with autism spectrum disorder (ASD) are prepared to start school this year after graduating from Hopebridge Autism Therapy...